Dr. Lingshi Tan is Chairman and CEO of dMed-Clinipace, a global full-service clinical research organization that is focused on bringing life-changing therapies to our global community through liberated clinical research.
Dr. Tan founded dMed in Shanghai in 2016 and took the company global via a merger with Clinipace in 2021. Prior to founding dMed, Dr. Tan was Pfizer’s VP of Worldwide Development Operations and Chairman and GM of Pfizer (China) Research & Development Co., Ltd. (CRDC). He was assigned from New York to Shanghai to establish the CRDC in 2005. Under Dr. Tan’s Leadership for 11 years, the CRDC grew to an organization of more than 1,000 professionals and became an integral part of Pfizer’s global R&D network, focusing on clinical development, safety, regulatory, and medical functions.
Dr. Lingshi Tan earned his PhD in Biostatistics from the University of Pittsburgh.